{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:15:36Z","timestamp":1791173736928,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2014,6,26]],"date-time":"2014-06-26T00:00:00Z","timestamp":1403740800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1007\/s00066-014-0698-x","type":"journal-article","created":{"date-parts":[[2014,6,25]],"date-time":"2014-06-25T16:43:09Z","timestamp":1403714589000},"page":"1169-1172","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Increased skin and mucosal toxicity in the combination of vemurafenib with radiation therapy","Erh\u00f6hte Haut- und Schleimhauttoxizit\u00e4t bei Kombination von Vemurafenib plus Strahlentherapie"],"prefix":"10.1007","volume":"190","author":[{"given":"Ricarda","family":"Merten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlen","family":"Haderlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luitpold","family":"Distel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Fietkau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Heinzerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Semrau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,26]]},"reference":[{"key":"698_CR1","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507\u20132516","journal-title":"N Engl J Med"},{"key":"698_CR2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0360-3016(99)00066-8","volume":"44","author":"MH Seegenschmiedt","year":"1999","unstructured":"Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A et al (1999) Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. Int J Radiat Oncol Biol Phys 44:607\u2013618","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"698_CR3","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s00066-010-2110-9","volume":"186","author":"K Freundt","year":"2010","unstructured":"Freundt K, Meyners T, Bajrovic A et al (2010) Radiotherapy for oligometastatic disease in patients with spinal cord compression (MSCC) from relatively radioresistant tumors. Strahlenther Onkol 186:218\u2013223","journal-title":"Strahlenther Onkol"},{"key":"698_CR4","first-page":"332","volume":"172","author":"I Wachenfeld","year":"1996","unstructured":"Wachenfeld I, Sanner G, Bottcher HD, Kollath J (1996) [The remineralization of the vertebral metastases of breast carcinoma after radiotherapy]. Strahlenther Onkol 172:332\u2013341","journal-title":"Strahlenther Onkol"},{"key":"698_CR5","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1562\/2005-08-02-TSN-635","volume":"82","author":"SG Coelho","year":"2006","unstructured":"Coelho SG, Miller SA, Zmudzka BZ, Beer JZ (2006) Quantification of UV-induced erythema and pigmentation using computer-assisted digital image evaluation. Photochem Photobiol 82:651\u2013655","journal-title":"Photochem Photobiol"},{"key":"698_CR6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.radonc.2006.10.012","volume":"81","author":"LV Distel","year":"2006","unstructured":"Distel LV, Neubauer S, Keller U, Sprung CN, Sauer R, Grabenbauer GG (2006) Individual differences in chromosomal aberrations after in vitro irradiation of cells from healthy individuals, cancer and cancer susceptibility syndrome patients. Radiother Oncol 81:257\u2013263","journal-title":"Radiother Oncol"},{"key":"698_CR7","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/jamadermatol.2013.4200","volume":"149","author":"L Boussemart","year":"2013","unstructured":"Boussemart L, Boivin C, Claveau J et al (2013) Vemurafenib and Radiosensitization. Jama Dermatology 149:855\u2013857","journal-title":"Jama Dermatology"},{"key":"698_CR8","doi-asserted-by":"crossref","unstructured":"Vanneste L, Wolter P, Van den Oord JJ, Stas M, Garmyn M (2014) Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients. J Eur Acad Dermatol Venereol (in press)","DOI":"10.1111\/jdv.12449"},{"key":"698_CR9","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdt015","volume":"24","author":"L Boussemart","year":"2013","unstructured":"Boussemart L, Routier E, Mateus C et al (2013) Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol 24:1691\u20131697","journal-title":"Ann Oncol"},{"key":"698_CR10","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1200\/JCO.2012.44.7755","volume":"31","author":"CJ Anker","year":"2013","unstructured":"Anker CJ, Ribas A, Grossmann AH et al (2013) Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J Clin Oncol 31:e283\u2013e287","journal-title":"J Clin Oncol"},{"key":"698_CR11","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1684\/ejd.2013.2108","volume":"23","author":"M Reigneau","year":"2013","unstructured":"Reigneau M, Granel-Brocard F, Geoffrois L et al (2013) Efflorescence of scalp cysts during vemurafenib treatment following brain radiation therapy: a radiation recall dermatitis? Eur J Dermatol 23:544\u2013555","journal-title":"Eur J Dermatol"},{"key":"698_CR12","doi-asserted-by":"crossref","unstructured":"Schulze B, Meissner M, Wolter M, Rodel C, Weiss C (2014) Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib. Two case reports. Strahlenther Onkol 190:229\u201332","DOI":"10.1007\/s00066-013-0474-3"},{"key":"698_CR13","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11060-013-1127-1","volume":"113","author":"A Narayana","year":"2013","unstructured":"Narayana A, Mathew M, Tam M et al (2013) Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 113:411\u2013416","journal-title":"J Neurooncol"},{"key":"698_CR14","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/(SICI)1096-9098(199708)65:4<284::AID-JSO11>3.0.CO;2-2","volume":"65","author":"S Friberg","year":"1997","unstructured":"Friberg S, Mattson S (1997) On the growth rates of human malignant tumors: implications for medical decision making. J Surg Oncol 65:284\u2013297","journal-title":"J Surg Oncol"},{"key":"698_CR15","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s10637-013-9928-9","volume":"31","author":"T Dasgupta","year":"2013","unstructured":"Dasgupta T, Haas-Kogan DA, Yang X et al (2013) Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas. Invest New Drugs 31:1136\u20131141","journal-title":"Invest New Drugs"},{"key":"698_CR16","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.radonc.2010.12.017","volume":"98","author":"MJ Sambade","year":"2011","unstructured":"Sambade MJ, Peters EC, Thomas NE, Kaufmann WK, Kimple RJ, Shields JM (2011) Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol 98:394\u2013399","journal-title":"Radiother Oncol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-014-0698-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00066-014-0698-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-014-0698-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T10:29:31Z","timestamp":1598005771000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00066-014-0698-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,26]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["698"],"URL":"https:\/\/doi.org\/10.1007\/s00066-014-0698-x","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,26]]}}}